Sio

Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share

Retrieved on: 
Friday, February 2, 2024
Common stock, DGCL, Certificate, Sio, State, Security (finance)

The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL").

Key Points: 
  • The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL").
  • In connection with the filing of the Certificate of Dissolution, effective as of the Effective Time, Sio will close its stock transfer books and discontinue recording transfers of its common stock, par value $0.00001 (the "Common Stock").
  • Sio currently expects to pay remaining cash to stockholders in one or more subsequent liquidating distributions, subject to uncertainties inherent in winding up its business.
  • Sio cannot provide any assurances with respect to the amounts of any such subsequent liquidating distributions or the timing thereof.

Sio Silica Corporation to Go Public via Business Combination With Pyrophyte Acquisition Corp., Accelerating Mission to Disrupt the Market for High-Purity Quartz Silica, a Critical Mineral in the World’s Transition to Net Zero

Retrieved on: 
Monday, November 13, 2023
Professional Services, Natural Resources, Mining, Minerals, Finance, Slate, Carbon, Economics, Acquisition, NYSE, Engineering, Business analyst, UBS, PIPE, Combination, Winnipeg Manitoba Temple, LLP, DLA Piper, Investment, Electronics, Piper, White & Case, Nature, Marketing, Natural gas, Semiconductor, Hand, Phase, Growth, Electricity, Business, Transport, ESG, Security (finance), Lithium, Renewable energy, Iron ore, Management, Sio, Stantec, Pyrophyte

Once the processing facility becomes operational, Sio expects to become a leading environmentally friendly producer of high-purity quartz silica, a unique natural resource and critical mineral.

Key Points: 
  • Once the processing facility becomes operational, Sio expects to become a leading environmentally friendly producer of high-purity quartz silica, a unique natural resource and critical mineral.
  • Anticipated applications for Sio’s high-purity quartz silica include photovoltaics, solar panels, semiconductors, electronics and batteries.
  • Expects to become a leader in the rapidly expanding high-purity quartz silica industry with no current plans to rely on government subsidies.
  • High-purity quartz silica currently represents a $30 billion total addressable market by 2030 for photovoltaics, solar panels, semiconductors and batteries.

Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

Retrieved on: 
Wednesday, December 14, 2022
Annual report, Person, Security (finance), Sale, ANY, Sio, IT, SIO, SIOX, Calendar, Name, Plan, File, Management, Dissolution

The Board of Directors has unanimously approved the dissolution and liquidation of the Company, subject to shareholder approval, pursuant to a Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”).

Key Points: 
  • The Board of Directors has unanimously approved the dissolution and liquidation of the Company, subject to shareholder approval, pursuant to a Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”).
  • The Plan of Dissolution contemplates an orderly wind down of the Company's business and operations.
  • Based on this estimated reserve, the Company will subsequently make liquidating distributions to shareholders as soon as practicable following the filing of the certificate of dissolution.
  • In connection with the proposed Plan of Dissolution, the Company intends to file with the SEC a proxy statement and other relevant materials.

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

Retrieved on: 
Wednesday, February 2, 2022
Glycogen storage disease, GM1 gangliosidoses, GM1, Private Securities Litigation Reform Act, Patient, Infant, NASDAQ, Organization, Sensor, MD, COVID-19, Type 2, Sio, Sandhoff disease, GLB1, Genetic testing, National, Orphan, Invitae, GM2, U.S. Securities and Exchange Commission, University of Massachusetts, Company, Neurodegeneration, GLOBE, Tay–Sachs disease, NIH, Imagination, Doctor of Philosophy, Industry, Security (finance), National Human Genome Research Institute, National Institutes of Health, SIOX, AAV, Pharmaceutical industry, Medicine

NEW YORK andDURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc.(NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present data in an oral platform presentation and two poster presentations at the 18th Annual WORLDSymposium 2022, to be held February 7-11, 2022.

Key Points: 
  • NEW YORK andDURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc.(NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present data in an oral platform presentation and two poster presentations at the 18th Annual WORLDSymposium 2022, to be held February 7-11, 2022.
  • The Company is also collaborating with Invitae, who will present a poster on the Detect LSD program.
  • The gene therapy is delivered intravenously, which has the potential to achieve a broad central and peripheral biodistribution.
  • Sio Gene Therapiescombines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.

Oxford Biomedica announces update to agreement with Sio Gene Therapies

Retrieved on: 
Monday, January 31, 2022
Center for Cell and Gene Therapy, Patient, Cell, Sio, Gene, OXB, Company, Interim, Oxford BioMedica, LSE, Solution, Pharmaceutical industry

Oxford, UK 31 January, 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, announced today that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinsons Disease.

Key Points: 
  • Oxford, UK 31 January, 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, announced today that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinsons Disease.
  • This follows Sios announcement today about the resignation of their CEO where Sio also indicates a constraint on resource requirements that has caused Sio to deprioritise the programme.
  • All rights shall be returned to Oxford Biomedica at no cost to the Company.
  • Oxford Biomedica originally out-licensed AXO-Lenti-PD (previously named OXB-102) to Sio Gene Therapies (previously called Axovant Gene Therapies), in June 2018.

Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease

Retrieved on: 
Thursday, November 11, 2021
Medication, Neurodegeneration, GMP, COVID-19, Industry, Private Securities Litigation Reform Act, Clinical trial, Organization, Security (finance), NASDAQ, MHRA, GM1, NEW, SIOX, Imagination, Company, U.S. Securities and Exchange Commission, GLOBE, Sio, Medicines and Healthcare products Regulatory Agency, Patient, AAV, Medical device, Pharmaceutical industry

NEW YORK and DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided a manufacturing and regulatory update for AXO-Lenti-PD, its clinical-stage gene therapy for Parkinson’s disease.

Key Points: 
  • With the successful manufacture of three batches, all of which achieved the target titer and have completed fill and finish, we now have a process that has generated sufficient clinical trial material for future clinical development.
  • The MHRA provided guidance on the:
    Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinsons disease, which affects millions of patients globally.
  • All forward-looking statements are based on estimates and assumptions by Sios management that, although Sio believes to be reasonable, are inherently uncertain.

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis

Retrieved on: 
Monday, November 1, 2021
Safety, Tay–Sachs disease, Fast track (FDA), COVID-19, SIOX, Sandhoff disease, Mutation, HEXB, Gene, Industry, Neurodegeneration, GM2, Organization, Fast Track, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, NASDAQ, FDA, Spinal cord, HEXA, Food, Life expectancy, Review, University of Massachusetts, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, GM1, Sio, GLOBE, Imagination, AAV, Infant, Pharmaceutical industry, Vaccine

NEW YORK and DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AXO-AAV-GM2, an investigational gene therapy for the treatment of early infantile, late infantile, and juvenile-onset Tay-Sachs and Sandhoff disease. The Fast Track designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.

Key Points: 
  • The Fast Track designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.
  • GM2 gangliosidosis is a set of rare, monogenic neurodegenerative lysosomal storage disorders caused by mutations in the genes that encode the enzyme -Hexosaminidase A.
  • AXO-AAV-GM2 has received Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation from theFood and Drug Administrationand is the only gene therapy in clinical development for all pediatric forms of GM2 gangliosidosis.
  • Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.

Sio Gene Therapies Announces Reorganization of R&D Group

Retrieved on: 
Thursday, October 21, 2021
COVID-19, SIOX, Research, SVP, Industry, Neurodegeneration, Joint Planning and Development Office, CNS, Organization, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, NASDAQ, Senior, Company, CEO, GM1, Sio, Growth, R, Development, Bureau of Oceans and International Environmental and Scientific Affairs, GLOBE, CMO, Imagination, AAV, Pharmaceutical industry

Gavin has been instrumental in leading our R&D organization through a period of growth as we evolved our business model towards the development of CNS gene therapies, said Pavan Cheruvu, M.D., Chief Executive Officer.

Key Points: 
  • Gavin has been instrumental in leading our R&D organization through a period of growth as we evolved our business model towards the development of CNS gene therapies, said Pavan Cheruvu, M.D., Chief Executive Officer.
  • I have enjoyed the time that I have spent at Sio and I am extremely proud of the R&D team that we have built.
  • Sio Gene Therapiescombines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies.

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis

Retrieved on: 
Thursday, October 21, 2021
Safety, Type 2, Fast track (FDA), COVID-19, SIOX, Orphan drug, Disease, Industry, Neurodegeneration, GM2, Tay–Sachs disease, Ill, Organization, Fast Track, Security (finance), U.S. Securities and Exchange Commission, ESGCT, Patient, NASDAQ, Private Securities Litigation Reform Act, FDA, GLB1, Glycogen storage disease, Food, GM1 gangliosidoses, Review, University of Massachusetts, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sandhoff disease, GM1, Biomarker, Sio, GLOBE, Imagination, AAV, 2012 Giro d'Italia, Stage 1 to Stage 11, Infant, Pharmaceutical industry

Receiving Fast Track Designation is a critical step in our mission to develop the first potential treatment for all pediatric forms of this rare, terminal disease.

Key Points: 
  • Receiving Fast Track Designation is a critical step in our mission to develop the first potential treatment for all pediatric forms of this rare, terminal disease.
  • AXO-AAV-GM1 has received both Orphan Drug Designation and Rare Pediatric Disease Designation from theFDAand is the only gene therapy in clinical development for all pediatric forms of GM1 gangliosidosis.
  • In 2018, Sio licensed exclusive worldwide rights from UMass Chan Medical Schoolfor the development and commercialization of gene therapy programs for GM1 gangliosidosis and GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases.
  • Sio Gene Therapiescombines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.

UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

Retrieved on: 
Monday, October 4, 2021
GM1 gangliosidoses, Food, Sandhoff disease, Neurodegeneration, Food and Drug Administration Amendments Act of 2007, HEXA, Security (finance), NASDAQ, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, University of Massachusetts Medical School, COVID-19, Patient, European Society of Gene and Cell Therapy, GM2, Infant, Central nervous system, Gene, Type 2, Tay–Sachs disease, SIOX, Company, University, Disease, Dopamine, Cell, GM1, Brain, Organization, AAV, Imagination, GLB1, HEXB, Sio, Industry, Enzyme, GLOBE, ESGCT, Pharmaceutical industry, Vaccine

The Company will also present a poster review of patient-level data up to 24 months from the Phase 1/2 study of AXO-Lenti-PD gene therapy for the treatment of Parkinsons disease.

Key Points: 
  • The Company will also present a poster review of patient-level data up to 24 months from the Phase 1/2 study of AXO-Lenti-PD gene therapy for the treatment of Parkinsons disease.
  • The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease as well.
  • Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinsons disease, which affects millions of patients globally.